

HEMO ORGANIC LIMITED

CIN: L24231GJ1992PLC018224

Registered Office Address: 8-A, Gulnar, Chinar - Gulnar Appt. V V Nagar Road Anand -388001

Email ID: drdineshpatel@rediffmail.com, Website: www.hemoorganicltd.com

Date: February 13, 2021

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sir,

Sub: Submission of Unaudited Financial Result of the Company for the quarter ended on December 31, 2020 along with Limited Review.

Ref: Hemo Organic Limited (Security ID: HEMORGANIC, Security Code: 524590)

In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the followings:

1. Unaudited Financial Results for the quarter ended on December 31, 2020;
2. Limited Review Report.

Kindly take the same on your record and disseminate the same on your website and oblige us.

Thanking You,

Yours faithfully,

For, Hemo Organic Limited


Dr. Dinesh Patel
Chairman and Managing Director
DIN: 00481641



Place: Anand

Hemo Organic Limited

CIN No. L24231GJ1992PLC018224

Registered Office: 8-A, Gulnar, Chinar-Gulnar Appt. V V Nagar Road Anand - 388001

UNAUDITED FINANCIAL RESULTS (STAND ALONE) FOR THE QUARTER ENDED ON DECEMBER 31, 2020

PART - I

(Rs. in lakhs)

Sr. No.	Particulars	Quarter ended			Nine Month ended		Year ended
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	INCOME						
	(a) Revenue from operations	0.03	0.78	7.89	0.80	14.70	27.72
	(b) Other Income	-	-	-	-	-	-
	Total Income	0.03	0.78	7.89	0.80	14.70	27.72
II.	EXPENSES						
	(a) Purchases of Stock-in-trade	0.05	0.50	4.44	0.55	10.04	19.03
	(b) Changes in stock of finished goods, work-in-progress and stock-in-trade	(0.04)	(0.06)	0.02	(0.09)	0.07	0.07
	(c) Employee benefit expense	1.26	0.65	0.65	2.55	1.94	2.58
	(d) Finance costs	-	-	-	-	0.26	-
	(e) Depreciation and amortisation expense	-	-	-	-	7.16	8.22
	(f) Other expenses	0.15	0.25	1.15	0.96	-	-
	Total Expenses (a to g)	1.42	1.34	6.26	3.97	19.47	29.90
III.	Profit before exceptional items and tax (I) - (II)	(1.39)	(0.56)	1.63	(3.17)	(4.77)	(2.18)
IV.	Exceptional Items	-	-	-	-	-	-
V.	Profit before tax (III) - (IV)	(1.39)	(0.56)	1.63	(3.17)	(4.77)	(2.18)
VI.	Tax Expense						
	(a) Current tax						
	- Current year	-	-	-	-	-	-
	- Prior years	-	-	-	-	-	-
	- MAT Credit (Entitlement)	-	-	-	-	-	-
	(b) Deferred tax	-	-	-	-	-	-
	Total tax expense	-	-	-	-	-	-
VII.	Profit after tax for the period (V) - (VI)	(1.39)	(0.56)	1.63	(3.17)	(4.77)	(2.18)
VIII.	Other comprehensive income						
	Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Remeasurement of the defined benefit liabilities	-	-	-	-	-	-
	Equity instruments through other comprehensive income	-	-	-	-	-	-
	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Other comprehensive income, net of tax	-	-	-	-	-	-
IX.	Total comprehensive income for the period	(1.39)	(0.56)	1.63	(3.17)	(4.77)	(2.18)
X.	Paid up equity share capital (Face value of Rs. 10 each)	346.59	346.59	346.59	346.59	346.59	346.59
XI.	Reserves i.e. Other Equity	-	-	-	-	-	-
XII.	Earnings per equity share (Face value of Rs. 10 each)						
	(1) Basic	(0.04)	(0.02)	0.05	(0.09)	(0.14)	(0.06)
	(2) Diluted	(0.04)	(0.02)	0.05	(0.09)	(0.14)	(0.06)

Date : 13/02/2021
Place: Anand



By order of the Board
Hemo Organic Limited


KRP
Dr. Dinesh Patel
DIN : 00481641
Managing Director

Notes : Hemo Organic Limited

- 1 The Company operates in a single segment . As per Ind AS 108 on segment reporting issued by the ICAI, the same is considered to constitute as single primary segment. Accordingly, the disclosure requirements of Ind AS 108 are not applicable.
- 2 The above standalone financial results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 13th February, 2021.
- 3 Earning per share for the quarter and year ended has been calculated as per weighted average formula and diluted Earning per share has been calculated considering proposed issue of equity shares on account of conversion of convertible securities.
- 4 Previous period figures have been regrouped and rearranged, whenever considered necessary.



By order of the Board
Hemo Organic Limited


Dineshbhai S. Patel

DIN: 00481641

Managing Director

MAAK & ASSOCIATES

Chartered Accountants

Limited Review Report on Unaudited Financial Results of the Hemo Organic Limited, pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
**The Board of Directors,
M/s Hemo Organic Limited**

We have reviewed the accompanying statement of unaudited financial results of M/s Hemo Organic Limited for the quarter ended December 31, 2020 and year to date from April 01, 2020, to December 31, 2020 being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, MAAK & Associates,
Chartered Accountants

Place: Ahmedabad

Date: 13th February, 2021

FRN No.135024W
Kenan Satyawadi
Partner



Mem.No.139533

UDIN: 21139533AAAAL7673